Lymphoma, B Cell Clinical Trial
Official title:
A Phase II Study of CHOP + Rituximab, With Intrathecal Methotrexate Followed by Radiotherapy in Patients With Primary Testicular Non-Hodgkin's Lymphoma
The primary objective assess the clinical activity of combination doxorubicin-containing chemotherapy plus monoclonal antibody anti-CD20 (Rituximab) plus intrathecal prophylactic chemotherapy and loco-regional radiotherapy in primary localised testicular DLCL and to assess the toxicity of this therapeutic strategy
n/a
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00523939 -
DepoCyt for Active Lymphomatous or Leukemic Meningitis
|
Phase 2 | |
Completed |
NCT02679196 -
The Safety, Pharmacokinetic and Pharmacodynamic Effect of KA2237 (PI3 Kinase p110β/δ Inhibitor) In B Cell Lymphoma
|
Phase 1 | |
Completed |
NCT00210314 -
Phase II Trial of Combined Modality Treatment in Primary Central Nervous System Lymphoma
|
Phase 2 | |
Not yet recruiting |
NCT02992834 -
Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for CD19+ B Cell Lymphoma
|
Phase 4 | |
Withdrawn |
NCT00210340 -
A Phase I Study of Intrathecal Rituximab in Patients With Lymphomatous Meningitis
|
Phase 1 |